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BACKGROUND: Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for
metastatic melanoma. In glioblastoma, promoter methylation of the counteracting DNA repair enzyme O
6-methylguanine-DNA-
methyltransferase (MGMT) correlates with survival of patients exposed to TMZ in combination with radiotherapy. For melanoma,
data are limited and controversial.
METHODS: Biopsy samples from 122 patients with metastatic melanoma being treated with TMZ in two multicenter studies of the
Dermatologic Cooperative Oncology Group were investigated for MGMT promoter methylation. We used the COBRA (combined
bisulphite restriction analysis) technique to determine aberrant methylation of CpG islands in small amounts of genomic DNA
isolated from paraffin-embedded tissue sections. To detect aberrant methylation, bisulphite-treated DNA was amplified by PCR,
enzyme restricted, and visualised by gel electrophoresis.
RESULTS: Correlation with clinical data from 117 evaluable patients in a best-response evaluation indicated no statistically significant
association between MGMT promoter methylation status and response. A methylated MGMT promoter was observed in 34.8% of
responders and 23.4% of non-responders (P¼0.29). In addition, no survival advantage for patients with a methylated MGMT
promoter was detectable (P¼0.79). Interestingly, we found a significant correlation between MGMT methylation and tolerance of
therapy. Patients with a methylated MGMT promoter had more severe adverse events, requiring more TMZ dose reductions or
discontinuations (P¼0.007; OR 2.7 (95% CI: 1.32–5.7)). Analysis of MGMT promoter methylation comparing primaries and different
metastases over the clinical course revealed no statistical difference (P¼0.49).
CONCLUSIONS: In advanced melanoma MGMT promoter, methylation correlates with tolerance of therapy, but not with clinical outcome.
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Therapy of metastatic melanoma still lacks efficacy because, other
than surgical resection of single metastases in a subgroup of
patients (Meyer et al, 2000; Wood et al, 2001), no therapeutic
approach significantly improves patients’ prognosis. Chemother-
apy of advanced melanoma has not yet shown any survival benefit
despite extensive efforts. Although polychemotherapy procedures
have achieved better response, the overall survival (OS) of patients
was not improved in comparison with monochemotherapy (Rass
and Hassel, 2009). Therefore, dacarbazine (DTIC) is still con-
sidered as the standard chemotherapy in melanoma (Dummer
et al, 2008). Temozolomide (TMZ) is the oral homologue of DTIC,
both act through the metabolite MTIC which subsequently induces
genetic alterations by alkylation. DNA repair enzymes can partly
reverse these effects and O
6-methylguanine-DNA-methyltransferase
(MGMT) counteracts TMZ-induced DNA alkylation.
Epigenetic silencing of the MGMT gene by promoter methyla-
tion of CpG islands was recently associated with prolonged
survival of patients with glioblastoma who received TMZ in
combination with radiotherapy (Hegi et al, 2005). For melanoma,
few studies, with limited numbers of patients, have analysed
MGMT activity and most of these did not focus on MGMT gene
methylation, but on MGMT protein expression levels and MGMT
activity. Middleton et al (1998) measured MGMT activity in
pretreatment melanoma biopsies from 33 patients and found no
predictive value for response to TMZ. Ma et al (2003) retro-
spectively investigated, by immunohistochemistry, MGMT protein
expression in melanoma metastases of 79 patients with
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smetastatic melanoma receiving DTIC as single agent or as part of
combination therapy, and reported an inverse correlation between
MGMT expression and clinical response with borderline signifi-
cance (P¼0.05). Recently, Rietschel et al (2008) treated 49
melanoma patients with an extended-dosing TMZ schedule and
assessed MGMT promoter methylation and protein expression by
methylation-specific pyrosequencing of the promoter and by
immunohistochemistry, respectively. These authors did not detect
any correlation of MGMT methylation with TMZ response.
Here, to evaluate the effect of MGMT methylation on response,
survival, and tolerance of TMZ treatment, we examined MGMT
gene silencing by methylation of its promoter using the COBRA
(combined bisulphite restriction analysis) technique in melanoma
biopsies from 122 patients with metastatic melanoma who had
been treated with TMZ in two large DeCOG (Dermatologic
Cooperative Oncology Group) multicenter studies.
MATERIALS AND METHODS
Patients and treatment
Melanoma biopsies were collected from patients in two randomised
multicenter studies, evaluating TMZ chemotherapy as first-line treat-
ment for stage IV melanoma from June 1992 to September 2006 carried
out by the DeCOG. Patients were treated by one of three different
therapy regimes: TMZ (200mgm
 2 per day for 5 consecutive days)
alone, in combination with subcutaneous interferon-a2b (5MUm
 2
three times a week) (Kaufmann et al, 2005), or in combination with
100mg subcutaneous pegylated interferon-a2b (Spieth et al, 2008).
Sampling of melanoma biopsies in both trial protocols was
approved by the responsible ethics committee. Of the 418 patients
enrolled in the two DeCOG trials, approximately one quarter (29.2%,
n¼122) were eligible, agreed to participate in this translational
research project, and provided additional written informed consent.
Participation in this translational research project was dependent on
evaluable biopsiable tumour, for example, in the form of skin or easily
reachable lymph node metastases. Archived paraffin-embedded tissue
sections were used for investigation of MGMT promoter methylation.
Outcome measurements
Response was evaluated using the bi-dimensional WHO criteria, as
described in the underlying clinical study protocols (Kaufmann et al,
2005; Spieth et al, 2008).The response rate (RR), defined as all patients
with a complete response (CR) or partial response (PR) as best
response to treatment, and the disease control rate (DCR), defined
as all patients with a CR, PR, or stable disease (SD) as best response to
treatment, were noted. For survival analysis, OS was measured from
the start of treatment to death or last observed date alive (censored
observation), and progression-free survival (PFS) was measured from
the start of treatment to the date of progression or death, which ever
occurred first, or last the date alive (censored observation).
Adverse events (AEs) of TMZ were monitored during treatment
and graded according to the Common Toxicity Criteria. Tolerance was
categorised, from excellent to poor, on the basis of the need to modify
treatment (defined per protocol) mainly because of haematologic
toxicity, for example, leucopenia and thrombocytopenia. ‘Excellent’
was defined as no AE reported, ‘good’ as mild AE reported without
any need for dose reduction, ‘satisfactory’ as any AE requiring dose
reduction, ‘moderate’ as therapy interrupted, followed by dose reduc-
tion, and ‘poor’ as any AE requiring discontinuation of treatment.
DNA extraction
To confirm that sufficient tumour tissue was available, haematoxylin
and eosin-stained slides were reviewed histologically by an indepen-
dent, blinded reviewer (HK). Only lesions with a tumour content of
more than 75% were included. For extraction of DNA from tissue
sections, we used the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. Deparaffinised
10-mm sections from each sample were used for extraction.
COBRA
Combined bisulphite restriction analysis was performed to
determine aberrant methylation of CpG islands in small amounts
of genomic DNA (Xiong and Laird, 1997). We introduced
methylation-dependent sequence differences by sodium bisulphite
treatment of genomic DNA using the EpiTect Bisulphite Kit
(Qiagen) according to manufacturer’s instructions. Primers used
for amplifying a 295-bp PCR product of the MGMT promoter
region were as follows: forward 5-TGGTAAATTAAGGTATA
GAGTTTTAGG and reverse 5-AAAACCTAAAAAAAACAAAAA
AAC. The PCR reactions were performed in a volume of 20ml
containing 1x Ready mix (Abgene, Cambridge, UK), 2ml bisulphite-
treated genomic DNA, 0.2mM of each primer, 1mM dNTPs
(Stratagene, Amsterdam, NL, USA), and 1U Thermoprime Plus
DNA polymerase (Abgene). We performed 35 cycles of amplifica-
tion at 951C for 30s, 551C for 30s, and 721C for 45s followed by a
final extension at 721C for 3min. PCR products were digested with
restriction enzyme TaqI (New England Biolabs, Ipswich, MA, USA)
and separated on agarose gels. For semiquantitative evaluation,
percentage of cleaved and, therefore, methylated DNA of the
extracted amount of genomic DNA was estimated as 0, 10, 25, 50, 75,
or 100% methylated (Figure 1a).
To ensure reliable results, several analyses from different blocks of
a tumour were examined, altogether 543 samples. Of these, 61 (11.2%)
could not be evaluated by COBRA analysis and were considered as
invalid in the analysis. The frequency of invalid samples and the
methylation status of the samples were not dependent on the study
c e n t r ew h e r et h eb i o p s yw a st a k e n( P¼0.11).
COBRA assay validation by sequencing
Five samples defined by COBRA as methylated and five samples
defined by COBRA as unmethylated were analysed by bisulphite
sequencing of 33 CpG islands for quality control. PCR products
were extracted from the gel and cloned using the TOPO TA cloning
kit (Invitrogen, Karlsruhe, Germany) according to manufacturer’s
instructions.
A degree of methylation X50% was observed in four of the five
samples classified as ‘methylated’ in COBRA analysis, and 9.9–11.8
methylated CpGs were observed in bisulphite sequencing. Only 10%
methylation with 3.8 methylated CpGs was observed in the fifth
sample. For the five samples classified as unmethylated by COBRA
analysis, methylation was from 3.1 to 7.7 methylated CpGs of the
33 CpGs analysed (Figure 1b, Supplementary Table 1). Together,
these results confirmed that the COBRA assay adequately represents
the genomic level of methylation of the MGMT promoter.
Immunohistochemistry
Immunohistochemistry was conducted on 4-mm sections of
formalin-fixed paraffin-embedded tissue. Sections were placed on
Superfrost Plus slides (Menzel, Braunschweig, Germany) and
baked for 1h at 601C. They were then deparaffinised, hydrated,
and placed in prewarmed citrate buffer and boiled in a microwave
oven for 20min. Still in the citrate buffer the slides were cooled at
room temperature for 20min. After incubation in blocking
solution (Zytomed ZytoChem-Plus AP Polymer Kit, Berlin,
Germany), 1:50 dilution of anti-MGMT clone MT23.2 (Zymed
Laboratories, Amsterdam, NL, USA) was added and the slides were
incubated overnight at 41C. Slides were washed in PBS and
antibody binding was visualised with Zytomed ZytoChem-Plus AP
Polymer Kit and Zytomed Permanent AP Red Kit, according to
manufacturer’s instructions. Substrate was incubated for 10min
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sand slides were counterstained with Mayers Ha ¨malaun for 30s and
mounted with Eukitt. As simultaneous negative control we used
sections stained without the first antibody. As positive control
colon carcinoma sections were used.
Statistical analysis
Patient characteristics of the study population (n¼122) were
analysed using descriptive statistical methods, that is, frequency
tables, median, and range. For each patient, the COBRA result from
the tumour sample with the highest tumour content in the paraffin
block was used. The methylation status of the first evaluable lesion
(primary tumour or metastasis) of a patient was examined for its
effects on the rate of RR and DCR using frequency tables
(contingency tables). Instead of using the six subgroups ‘0, 10, 25,
50, 75, and 100% methylation’ as evaluated by COBRA, the
subgroups were split into two groups, ‘methylated’ and ‘unmethy-
lated’, because the number of patients did not allow analysis of so
many subgroups. Fisher’s exact test was used to test for differences
between the methylated and non-methylated groups. Overall
survival and PFS were analysed by the Kaplan–Meier method,
and the two methylation groups were compared using the two-sided
log-rank test. The prognostic effect of MGMT promoter methylation
and clinical factors was investigated by use of the multivariable
proportional hazard regression model (Cox regression). Differences
between methylation outcomes of patients were examined by use of
generalised estimation equations for correlated and repeated
measurement data. These multivariate and multilevel data of the
primary tumour (when available) and multiple metastases were
analysed with the SAS procedure GENMOD, assuming an exchange-
able correlation structure (Diggle et al, 1994). Taking into account
the explorative nature of this investigation, a significance level of
0.05 was used throughout. All statistical analyses were performed
using SAS version 9.2 (Heidelberg, Germany).
RESULTS
One-hundred and twenty-two patients were included in this
translational research project to evaluate MGMT promoter
methylation. In this patient population, 63.1% were male and the
mean age was 56 years (s.d. 12.8; range 23–80 years). Of these
patients, 63.1% were treated with chemoimmune therapy, namely,
TMZ plus interferon. Compared with the complete study popula-
tion of the two DeCOG trials, there were no great differences
between gender, age, or measures of clinical outcome such as RR
or OS (Table 1) (Kaufmann et al, 2005; Spieth et al, 2008).
MGMT promoter methylation did not differ significantly
between primary tumours and metastases of the melanoma
Because little is yet known about possible differences between
MGMT promoter methylation of different metastases or over the
clinical course, we analysed the MGMT methylation status of
primary tumours and subsequent metastases of a patient. In this
evaluation, up to nine different metastases of a patient and
different samples of each metastasis were used to investigate
variation of methylation between primary and metastases.
Table 1 Comparison of the study populations in the two DeCOG trials
with the patients in this translational research project
Study
Number
of
patients
Gender
male
(%)
Age
median
(years)
Response
rate (%)
Overall
survival
(months)
DeCOG I
(2 arms:
TMZ/TMZ+IFN)
(Kaufmann et al,
2005)
294 64.0/59.4
P¼0.45
56.0/54.5
P¼0.86
13.4/24.1
P¼0.036
8.4/9.7
P¼0.16
DeCOG II
(TMZ+pegIFN)
(Spieth et al,
2008)
124 66.7 55.5 18.1 9.4
Translational
research project
122 63.1 56 19.6 9.7/10.5
(meth/unmeth
MGMT)
Abbreviations: DeCOG¼Dermatologic Cooperative Oncology Group; MGMT¼
O
6-methylguanine-DNA-methyltransferase; TMZ¼temozolomide; IFN¼interferon-a;
pegIFN¼pegylated interferon-a; meth/unmeth¼methylated/unmethylated.
Sample 648
COBRA 50% methylated
Sample 39
COBRA unmethylated
7
10
11
13
14
15
17
9
16
12
2
3
4
6
7
8
9
10
11
1
Unmethylated CpG Methylated CpG
Methylated CpG-producing enzyme restriction site
539 540 541 542 543
25 50 0 10 0M
MGMT COBRA results
% DNA methylation
Sample number
Figure 1 (A) COBRA results from five representative samples. Tumour DNA was extracted from paraffin-embedded tissue sections, bisulphite treated,
amplified by PCR, Taq1 digested, and visualised by gel electrophoresis. For semiquantitative evaluation, percentage of cleaved and, therefore, methylated
DNA (lower band) was estimated as 0, 10, 25, 50, 75, or 100% methylated (see numbers; M¼marker); (B) Examples of bisulphite sequencing results for
10 clones of unmethylated (sample 39) and methylated (sample 648) samples in COBRA analysis: For quality control, PCR products of the COBRA analysis
were extracted from the gel and cloned; each circle represents a CpG island of the MGMT promoter. The ‘unmethylated’ sample by COBRA analysis
revealed, on average, 3.4 methylated CpG islands, the ‘methylated’ sample 11.8, indicative of reliable COBRA results.
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sAltogether, 480 samples from 65 patients with at least two
metastases were analysed. Of these, 209 samples were methylated
and 271 unmethylated. Statistical analysis failed to reveal any
significant difference between the MGMT methylation status of
primary tumours and metastases or between different metastases
of a patient (P¼0.49 after adjustment for age and gender, Table 2).
Hence, the MGMT methylation status seems not to change with
clinical course, and for evaluation of the MGMT methylation status
of the patient’s melanoma the primary or a metastasis can be taken.
In addition to MGMT promoter methylation, we examined
several tissue samples for MGMT protein expression levels by
immunohistochemistry. O
6-methylguanine-DNA-methyltransferase
expression was very low in all the melanoma samples tested,
irrespective of the MGMT promoter methylation status determined
or clinical outcome (Figure 2, Supplementary Table 2).
MGMT promoter methylation did not correlate with
clinical outcome
For statistical analysis of clinical response and patient survival, the
first evaluable primary or metastasis of a patient was always
included in the calculation to preserve the sample size. If, for
methodological reasons, no valid methylation status was observed
for that first sample the next patient sample was taken. Of 117
evaluable patients (clinical data were missing for five patients), six
patients (5.1%) responded to treatment with a CR, 17 (14.5%) with
a PR, 31 (26.5%) had SD, and 63 (53.9%) had progressive disease
(PD) as best response to therapy.
Combined bisulphite restriction analysis evaluation of these samples
revealed different grades of MGMT promoter methylation of the
tumour DNA: 76 of 122 biopsy samples (62.3%) were unmethyl-
ated and 46 (37.7%) were methylated. The investigation included
27 primaries (22.1%) and 95 metastases. More information about
patients and the clinical data are given in Table 3.
Correlation of the MGMT methylation status with clinical response
to TMZ revealed no significant difference between therapy responders
and non-responders in multivaria t ea n a l y s i sa d j u s t e df o ra g ea n d
gender (P¼0.26). Of 23 patients with either CR or PR as best response
to therapy, 11 patients (47.8%) had a methylated MGMT promoter
compared with 32 of 94 (34.0%) in the non-responder group
(SDþPD). With regard to DCR, MGMT promoter methylation was
observed for 42.6% of patients in group SDþPRþCR compared with
31.7% in the PD group (P¼0.25) (Table 3).
Kaplan–Meier curves revealed median OS of 10.5 months (95%
CI: 7.2–12.5) for patients whose tumours were methylated at the
MGMT promoter compared with a median of 9.7 months (95% CI:
7.6–11.4) for patients with an unmethylated MGMT promoter
(Figure 3). There was, therefore, no significant difference between
OS in these two groups (log-rank test: P¼0.79). This finding was
confirmed by multivariate analysis after adjustment for age and
gender (Cox regression: P¼0.31; HR 0.955 with 95% CI: 0.63–1.45).
Similar results were obtained for PFS. Here, the Kaplan–
Meier curves of the two patient groups were almost equal with a
median time to progression of 3.4 months (95% CI: 2.4–4.0) for
patients with an unmethylated promoter and 3.9 months (95% CI:
2.3–5.3) for patients with a methylated MGMT promoter (log-rank
test: P¼0.60) (Figure 3). Again this was confirmed by multivariate
analysis after adjustment for age and gender (Cox regression:
P¼0.40; HR 0.91 with 95% CI: 0.61–1.36).
Table 2 Results from determination of MGMT methylation of primaries
and metastases
Groups
All
tumour
samples
(n)
Primaries
(n,% )
Metastases
(n,% )
Mean
difference
(95% CI)
Level of
significance
between
groups
All 480 59 421 P¼0.491
a
Methylated 209 24 185  0.66
Unmethylated 271 35 236 ( 2.55/1.22)
Abbreviations: CI¼confidence interval; MGMT¼O
6-methylguanine-DNA-methyl-
transferase.
aAfter adjustment for age and gender.
Figure 2 O
6-methylguanine-DNA-methyltransferase expression by immunohistology in melanoma metastases with MGMT promotor methylation status
analysed by COBRA. (A) COBRA analysis suggested unmethylated MGMT promotor; (B) or a methylated MGMT promotor. In comparision as positive
staining control a colonic cancer biopsy was chosen (C). The immunohistochemical staining was carried out on paraffin-embedded tissue using a monoclonal
anti-MGMT antibody and a Polymer-based Permanent AP Red Kit. Slides were shortly counterstained with Ha ¨malaun.
Table 3 Description of patient population with methylated and unmethylated MGMT promoters
Groups
Mean age
(range) Gender Treatment RR
a (n¼117) DCR
a (n¼117)
All (n¼122) 56 years
(23–80)
63.1% male
(n¼77)
63.1% TMZ+INF
(n¼77)
CR+PR: 19.7% (n¼23),
SD+PD: 80.3% (n¼94)
CR+PR+SD: 46.2% (n¼54),
PD: 53.8% (n¼63)
Methylated (n¼46, 37.7%) 58.1 years
(23–80)
58.7% male
(n¼27)
67.4%
(n¼31)
CR+PR: 25.6% (n¼11),
SD+PD: 74.4% (n¼32)
CR+PR+SD: 53.5% (n¼23),
PD: 46.5% (n¼20)
Unmethylated (n¼76, 62.3%) 54.7 years
(30–78)
65.8% male
(n¼50)
60.5%
(n¼46)
CR+PR: 16.2% (n¼12),
SD+PD: 83.8% (n¼62)
CR+PR+SD: 41.9% (n¼31),
PD: 58.1% (n¼43)
Level of significance of differences
between groups
P¼0.29 P¼0.52 P¼0.56 P¼0.26 P¼0.25
Abbreviations: TMZ¼temozolomide; INF¼interferon-a;R R¼response rate; DCR¼disease control rate; CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease; MGMT¼O
6-methylguanine-DNA-methyltransferase.
aFive patients with missing clinical data at best response to therapy.
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sIn univariate analysis we searched for other factors with possible
effect on either methylation status or patient survival. Addition of
interferon-a to TMZ treatment suggested a trend to better therapy
response (P¼0.10; OR 0.41; 95% CI: 0.14–1.2), but no effect for
OS (P¼0.77; HR 1.06; 95% CI: 0.7–1.6) or for PFS (P¼0.53; HR
1.14; 95% CI: 0.76–1.7). This is in agreement with the clinical
findings of the DeCOG trial, which revealed a better response for
the combination with interferon that did not translate into a
survival benefit (Kaufmann et al, 2005; Spieth et al, 2008).
In conclusion, the data reveal that MGMT promoter methylation
does not correlate with clinical outcome of TMZ treatment in stage
IV melanoma.
MGMT promoter methylation correlated with tolerance of
TMZ treatment
Tolerance of therapy was documented in 111 of the 122 patients,
and AEs were grouped into five categories including dose reduc-
tion, therapy interruption, and discontinuation (Table 4, Figure 4).
Interestingly, we found an effect of MGMT promoter methylation
status of the tumour biopsy on patients’ tolerance of TMZ. Patients
with an unmethylated MGMT promoter developed fewer AEs than
those with a methylated promoter. This was observed in univariate
analysis (Table 3; P¼0.045) and was confirmed by multivariate
analysis which indicated that tolerance was associated with methyla-
tion status (P¼0.007; OR 2.7 with 95% CI: 1.32–5.7) and gender
(P¼0.001; OR 3.4 with 95% CI: 1.63–7.11) but not with age (P¼0.86).
An unmethylated MGMT promoter was shown to be associated with,
on average, 2.7-fold better tolerance of therapy (Figure 4).
DISCUSSION
Gene promoter methylation of the DNA repair enzyme MGMT
correlates with clinical response to TMZ treatment in combination
with radiotherapy and significantly alters OS of patients with
glioblastoma (Hegi et al, 2005). In melanoma, results are still
controversial. Using a biochemical method to measure MGMT
activity, Middleton et al (1998) found no correlation with clinical
response. In contrast, Ma et al (2003) reported immunohisto-
chemical staining with a monoclonal antibody and described an
association of MGMT expression level with clinical response to
DTIC chemotherapy (P¼0.05), noting that MGMT nuclear
staining was difficult to evaluate. Rietschel et al (2008) also
investigated MGMT expression by a methylation-dependent
method and by immunohistochemistry and found no association
with response in a limited number of patients. Here, we
investigated MGMT gene silencing by methylation of its promoter
using the COBRA technique for 122 metastatic melanoma patients
with first-line TMZ treatment in two large multicenter trials. No
association between MGMT promoter methylation and clinical
response was detectable. In addition, neither PFS nor OS differed
between patients with a methylated or unmethylated MGMT
promoter region in the melanoma biopsy. Immunohistochemical
analysis of MGMT expression in a series of melanoma biopsies
using a specific monoclonal antibody revealed generally low
MGMT expression, irrespective of MGMT promoter methylation
status. In accordance with this observation, melanoma is known to
belong to tumours with the lowest average MGMT expression (in
contrast, for example, with colon and breast carcinoma) (Kaina
et al, 2007). Previous in vitro studies on melanoma cell lines could
find expression of MGMT (Mhaidat et al, 2007). However, cell lines
might have changed their expression patterns with culturing. It is
therefore conceivable that low MGMT expression levels in
melanoma also reflect minor importance of MGMT for TMZ
resistance in this disease. In line with this concept is the
observation that addition of the MGMT inhibitor O
6-bromothe-
nylguanine (lomeguatrib) to TMZ in a phase II trial did not
improve RR or PFS (Ranson et al, 2007). In melanoma cell lines,
TMZ has been shown to induce cell cycle arrest associated with
accumulation of p53 and p21, but which is not followed by
apoptosis (Mhaidat et al, 2007). Chemoresistance to TMZ could,
therefore, also be based on other resistance mechanisms, for
example, the known apoptosis resistance of melanomas in general,
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Figure 3 Kaplan–Meier curves for overall survival (OS, A) and progression-free survival (PFS, B) for the two groups of patients with methylated or
unmethylated MGMT promoters, respectively, revealing no significant difference.
Table 4 Tolerance of TMZ, and MGMT methylation status
Groups Excellent Good Satisfactory Moderate Poor
v
2
(Fisher’s
exact)
Methylated
(n¼43), n (%)
4 (9.3) 18 (41.9) 9 (21.0) 7 (16.3) 5 (11.6) P¼0.045
Unmethylated
(n¼68), n (%)
17 (25.0) 30 (44.1) 14 (20.6) 6 (8.8) 1 (1.5)
Abbreviations: MGMT¼O
6-methylguanine-DNA-methyltransferase; TMZ¼temo-
zolomide. Tolerance during TMZ treatment of patients with a methylated or
unmethylated MGMT promoter. Tolerance groups were defined by the grade of
adverse event, which resulted in treatment modifications: Excellent¼no adverse
events, Good¼adverse event, no dose reduction required, Satisfactory¼dose
reduction required, Moderate¼therapy interrupted, followed by subsequent dose
reduction, and Poor¼therapy discontinued. Patients with unmethylated MGMT
promoter tolerated therapy significantly better (P¼0.045) (Figure 3).
MGMT gene promoter methylation in melanoma
JC Hassel et al
824
British Journal of Cancer (2010) 103(6), 820–826 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sand not so much be modulated by the low MGMT activity. In
addition, TMZ-induced O
6-methylation causes double-strand
breaks, which could be repaired by other DNA repair enzymes
such as the homologous repair (HR) enzymes XRCC2 and BRCA2.
Roos et al (2009) could show that HR-mutated glioma cells are
hypersensitive to O
6-methylguanin triggered cell death induced by
TMZ. Therefore, HR can be considered as a mechanism that causes
tolerance of O
6-methylguanin adducts. BRCA2 mutations are not
very common in melanoma, but among carriers of the N991D
change of the BRCA2 gene the risk to develop melanoma is
increased (Debniak et al, 2008). However, whether these patients
were sensitive to TMZ is not reported.
The MGMT methylation status of the tumour could therefore be
more a patient phenotype having little to do with MGMT
expression level and TMZ chemoresistance. In agreement with
this interpretation, we found no significant differences between the
MGMT methylation status of melanoma primaries or metastases in
65 patients with up to 9 metastases. This confirms the findings of
Rastetter et al (2007) but is in contrast with those of Kohonen-
Corish et al (2006) who described heterogeneity in MGMT gene
methylation between melanoma metastases from the same patient
for a limited number of 11 patients.
O
6-methylguanine-DNA-methyltransferase methylation status as
a host-specific rather than tumour-specific condition explains why
MGMT promoter methylation of the tumour was highly associated
with TMZ tolerance in patients requiring more dose reductions
or discontinuations. O
6-methylguanine-DNA-methyltransferase
expression in peripheral blood mononuclear cells (PBMCs) is a
good surrogate marker for that in blood progenitor cells (Gerson
et al, 1985) and could explain TMZ haematologic toxicity.
Combination of alkylating agents with MGMT inhibitors, for
example, the pseudosubstrates O
6-benzylguanine and lomeguatrib,
led to increased occurrence of AEs and dose reductions in clinical
trials. The effort to improve chemosensitivity towards alkylating
agents has therefore been paralleled by increased toxicity (Ranson
et al, 2007; Tawbi and Kirkwood, 2007). Toxicity is in contrast with
response of melanoma correlated with MGMT activity.
In glioblastoma patients, the correlation between DNA methyla-
tion in tumour tissue and free circulating DNA of sera was highly
significant (Balana et al, 2003; Ramirez et al, 2003). Hence, besides
evaluation of MGMT methylation in PBMCs, future investigations
should test whether the toxicity of TMZ could possibly be
predicted by measuring the MGMT methylation status of free
DNA in the serum. This could lead to an easy tool for prediction of
a patient’s tolerance of planned chemotherapy with TMZ and lead
to preselection of patients to be treated.
STATEMENT OF TRANSLATIONAL RELEVANCE
This work demonstrates for the first time that, in melanoma,
silencing of the MGMT promoter correlates with TMZ toxicity.
This could mean that MGMT methylation of the tumour is
host-specific rather than tumour-specific. In agreement with this
we found no difference between MGMT methylation status in
primaries and different metastases of a patient. In contrast to
glioblastoma, we found that MGMT methylation status was not
important in TMZ response or survival of patients.
Because DTIC and TMZ are still the standard therapy for
melanoma, however, determination of MGMT methylation could
indicate for which patients these treatments should not be given,
because of expected toxicity. This could possibly be measured in
patients’ blood and should be confirmed in a prospective trial.
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